Designing Drugs to Target the Brain's Endocannabinoid Breakdown Enzymes | Research

The takeaway

Researchers tested compounds that inhibited the enzymes breaking down the brain's own cannabinoids, finding candidates that could enhance endocannabinoid signaling without directly activating cannabinoid receptors.

Read this if you are interested in how scientists are developing cannabis-based medicines that work without getting you high.

Lead compounds enhanced endocannabinoid signaling without CB1 activation at therapeutic doses

What the researchers found

The study systematically tested analogues of the endocannabinoid 2-AG for their ability to inhibit two key enzymes: monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), which break down the body's own cannabinoids. Several compounds were identified that inhibited these enzymes without directly activating CB1 receptors, meaning they could potentially enhance endocannabinoid signaling without producing psychoactive effects.

Compounds alpha-Methyl-1-AG, O-2203, and O-2204 were identified as promising leads for developing selective MAGL inhibitors, as they only weakly interacted with CB1 receptors and showed no central cannabinoid receptor activation in vivo at tested doses.

Why it matters

Rather than introducing external cannabinoids (like THC), this research aimed to enhance the body's own cannabinoid system by preventing the breakdown of endocannabinoids. This approach could potentially provide therapeutic benefits without psychoactive effects, representing a fundamentally different strategy for cannabinoid-based medicine.

The numbers in context

2-AG IC50: 13 micromolar for MAGL. Lead compounds: alpha-Methyl-1-AG, O-2203, O-2204 with Ki values of 1.8, 3.7, and 3.2 micromolar for CB1 (vs 0.24 for 1-AG). No central effects at doses up to 30 mg/kg IV.

How the study worked

This was a pharmacological study using in vitro enzyme assays and in vivo animal testing. Analogues of 2-AG were tested for inhibition of MAGL and FAAH using cytosolic and membrane-bound preparations. CB1 receptor binding was assessed in CHO cells, and in vivo cannabinoid activity was tested at doses up to 30 mg/kg IV.

What this study cannot tell us

In vitro enzyme inhibition does not guarantee in vivo therapeutic efficacy. The compounds were tested only in acute settings; chronic effects were not assessed. The selectivity between MAGL and FAAH was modest for most compounds tested.

How to read the evidence

This is a preclinical pharmacological study providing preliminary evidence for drug development leads.

When this study was published

Published in 2004. Endocannabinoid enzyme inhibitors have continued to be developed as potential non-psychoactive therapeutics.

The bigger picture

MAGL and FAAH inhibitors have become important research tools and potential therapeutic agents. FAAH inhibitors progressed to human clinical trials for pain and anxiety, though one trial was halted due to serious adverse events (BIA 10-2474). The concept of enhancing endocannabinoid tone rather than directly activating receptors remains a promising therapeutic strategy.

Questions still open

Have MAGL-selective inhibitors progressed to clinical trials? Can endocannabinoid enhancement provide therapeutic benefits comparable to direct cannabinoid receptor agonists?

Common questions

Can you get the benefits of cannabis without getting high?

This research aimed to do exactly that. By inhibiting enzymes that break down the body's own cannabinoids rather than introducing THC, the approach could potentially enhance natural cannabinoid signaling without psychoactive effects.

What are MAGL and FAAH?

They are enzymes that break down the body's own endocannabinoids (2-AG and anandamide). Inhibiting these enzymes allows endocannabinoids to remain active longer, potentially enhancing their natural therapeutic effects.

Read the original research

Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol.

British journal of pharmacology, 143(6), 774-84

View on PubMed ↗

Citation

Ghafouri, Nazdar; Tiger, Gunnar; Razdan, Raj K; Mahadevan, Anu; Pertwee, Roger G; Martin, Billy R; Fowler, Christopher J. (2004). Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol.. British journal of pharmacology, 143(6), 774-84.